Literature DB >> 12404569

The influence of three months of methylphenidate treatment on platelet-poor plasma biogenic amine levels in boys with attention deficit hyperactivity disorder.

B. Spivak1, Y. Vered, R. Yoran-Hegesh, E. Graff, E. Averbuch, S. Vinokurow, A. Weizman, R. Mester.   

Abstract

Attention deficit hyperactivity disorder (ADHD) is related to dysregulation in the activity of brain monoamines. The aim of the present study was to assess the impact of three months' methylphenidate (MPH) treatment on platelet-poor plasma (PPP) norepinephrine (NE), dopa and serotonin (5-HT) levels as well as on ADHD symptomatology. Three months of MPH treatment in 16 ADHD boys, aged 11.4 +/- 1.6 years, resulted in a significant reduction in PPP NE levels (p < 0.05). A tendency towards a reduction of PPP 5-HT and dopa levels was detected (p < 0.1 for both). The decrease in PPP biogenic amine levels after three months of MPH treatment was accompanied by a significant reduction in all psychometric characteristics of ADHD. This result indicates the possible role of overactivity of the noradrenergic system in the pathophysiology of ADHD and suggests that the MPH therapeutic action may be related to stimulant-induced inhibitory effect on the noradrenergic system. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Year:  2001        PMID： 12404569     DOI： 10.1002/hup.298

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN： 0885-6222            Impact factor:   1.672


  5 in total

1.  Motor timing deficits in community and clinical boys with hyperactive behavior: the effect of methylphenidate on motor timing.

Authors:  Katya Rubia; Janet Noorloos; Anna Smith; Boudewijn Gunning; Joseph Sergeant
Journal:  J Abnorm Child Psychol       Date:  2003-06

2.  Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial.

Authors:  Jolien Fleur Leijenaar; Geert Jan Groeneveld; Wiesje Maria van der Flier; Philip Scheltens; Erica Surya Klaassen; Henry Chanoch Weinstein; Geert Jan Biessels; Frederik Barkhof; Niels Daniël Prins
Journal:  JMIR Res Protoc       Date:  2018-03-20

3.  Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI.

Authors:  Jolien F Leijenaar; Geert Jan Groeneveld; Erica S Klaassen; Anna E Leeuwis; Philip Scheltens; Henry C Weinstein; Joop M A van Gerven; Frederik Barkhof; Wiesje M van der Flier; Niels D Prins
Journal:  Alzheimers Res Ther       Date:  2020-01-07       Impact factor: 6.982

Review 4.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09

5.  Methylphenidate has mild hyperglycemic and hypokalemia effects and increases leukocyte and neutrophil counts.

Authors:  Gideon Charach; Eli Karniel; Itamar Grosskopf; Alexander Rabinovich; Lior Charach
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.